Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked hard but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past few shares of mine. My first CytoDyn post, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set out the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire job interview which I came away with an inadequate viewpoint of the company.

Irony of irony, my poor impression of the business has grown steadily, although the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this expertise as well as associated intellectual property coming from Progenics to CytoDyn, as well as roughly twenty five million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 zillion) and the very first new drug program endorsement ($five million), and also royalty payments of five percent of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with multiple therapies and numerous indications, it’s this individual therapy as well as a “broad pipeline of indications” as it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

Its opening banner on its site (below) shows an energetic business with diverse interests albeit centered on leronlimab, several disease types, multiple publications and multiple delivering presentations.

Might all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the very beginning of the interest of mine in this particular organization. Judging by the multiples of thousands of various comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a traditional battleground, or perhaps some could say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *